Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors

Abstract Introduction A combination of targeted anticancer drugs with cytotoxic therapy can potentially overcome multidrug resistance. The multi-target kinase inhibitor sorafenib demonstrates synergistic activity when combined with chemotherapeutics in preclinical models. This phase I trial aimed to...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daphne W. M. Voogd, Merel J. J. Lucassen, Ruud van der Noll, Sybrand W. J. Zielhuis, David Boss, Jos H. Beijnen, Hilde Rosing, Matthijs Tibben, Alwin D. R. Huitema, Jan H. M. Schellens, Neeltje Steeghs
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2025-05-01
coleção:	Oncology and Therapy
Assuntos:	Medical oncology Phase I clinical trial Targeted therapy Protein kinase inhibitor
Acesso em linha:	https://doi.org/10.1007/s40487-025-00340-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!